ArcBest (ARCB) Reaches $49.20 After 7.00% Up Move; Shorts at Neovasc Inchares (NVCN) Raised By 121.27%

May 21, 2018 - By Michael Collier

Neovasc Inc. (NASDAQ:NVCN) Logo

The stock of ArcBest Corporation (NASDAQ:ARCB) is a huge mover today! The stock increased 3.04% or $1.45 during the last trading session, reaching $49.2. About 101,158 shares traded. ArcBest Corporation (NASDAQ:ARCB) has risen 23.82% since May 21, 2017 and is uptrending. It has outperformed by 12.27% the S&P500.The move comes after 6 months positive chart setup for the $1.26B company. It was reported on May, 21 by Barchart.com. We have $52.64 PT which if reached, will make NASDAQ:ARCB worth $88.34M more.

Neovasc Inchares (NASDAQ:NVCN) had an increase of 121.27% in short interest. NVCN’s SI was 10.23M shares in May as released by FINRA. Its up 121.27% from 4.62M shares previously. With 85.16M avg volume, 0 days are for Neovasc Inchares (NASDAQ:NVCN)’s short sellers to cover NVCN’s short positions. The SI to Neovasc Inchares’s float is 19%. The stock increased 9.24% or $0.0029 during the last trading session, reaching $0.0343. About 41.99 million shares traded. Neovasc Inc. (NASDAQ:NVCN) has declined 92.17% since May 21, 2017 and is downtrending. It has underperformed by 103.72% the S&P500.

More news for Neovasc Inc. (NASDAQ:NVCN) were recently published by: Streetinsider.com, which released: “Neovasc (NVCN) Urges Shareholders to Vote In Favor of Proposed Reverse Stock Split” on May 15, 2018. Seekingalpha.com‘s article titled: “Neovasc’s (NVCN) CEO Fred Colen on Q1 2018 Results – Earnings Call Transcript” and published on May 11, 2018 is yet another important article.

Neovasc Inc., a specialty medical device company, develops, makes, and markets cardiovascular devices worldwide. The company has market cap of $60.53 million. The Company’s products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. It currently has negative earnings. The firm also provides Peripatch biological tissue products that are used as components in third-party medical products, such as transcatheter heart valves for industry partners and other customers.

Among 4 analysts covering Neovasc (NASDAQ:NVCN), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Neovasc had 9 analyst reports since August 12, 2015 according to SRatingsIntel. The firm has “Buy” rating by Ladenburg Thalmann given on Thursday, December 10. Zacks downgraded Neovasc Inc. (NASDAQ:NVCN) on Wednesday, August 12 to “Buy” rating. The firm has “Buy” rating by Canaccord Genuity given on Thursday, March 29. The stock has “Buy” rating by Canaccord Genuity on Tuesday, August 25. Ladenburg Thalmann downgraded Neovasc Inc. (NASDAQ:NVCN) on Friday, May 20 to “Neutral” rating. JMP Securities initiated the shares of NVCN in report on Wednesday, October 7 with “Market Outperform” rating. Leerink Swann maintained Neovasc Inc. (NASDAQ:NVCN) rating on Thursday, March 29. Leerink Swann has “Outperform” rating and $2 target. Zacks downgraded Neovasc Inc. (NASDAQ:NVCN) on Wednesday, August 26 to “Hold” rating.

More notable recent ArcBest Corporation (NASDAQ:ARCB) news were published by: Nasdaq.com which released: “Analysis: Positioning to Benefit within Apogee Enterprises, ArcBest, Buckle, Career Education, Abercrombie & Fitch …” on May 17, 2018, also Prnewswire.com with their article: “ArcBest Among Transport Topics’ Top Freight Brokerage Firms of 2018” published on May 14, 2018, Benzinga.com published: “50 Biggest Movers From Friday” on May 14, 2018. More interesting news about ArcBest Corporation (NASDAQ:ARCB) were released by: Benzinga.com and their article: “38 Stocks Moving In Friday’s Mid-Day Session” published on May 11, 2018 as well as Benzinga.com‘s news article titled: “Earnings Scheduled For May 10, 2018” with publication date: May 10, 2018.

Among 10 analysts covering Arcbest Corporation (NASDAQ:ARCB), 0 have Buy rating, 0 Sell and 10 Hold. Therefore 0 are positive. Arcbest Corporation had 43 analyst reports since August 5, 2015 according to SRatingsIntel. The stock of ArcBest Corporation (NASDAQ:ARCB) earned “Neutral” rating by Bank of America on Monday, November 6. The stock of ArcBest Corporation (NASDAQ:ARCB) has “Equal-Weight” rating given on Thursday, January 7 by Stephens. The firm earned “Hold” rating on Tuesday, April 3 by Stifel Nicolaus. Stifel Nicolaus maintained the stock with “Hold” rating in Tuesday, September 19 report. On Wednesday, December 13 the stock rating was downgraded by Stifel Nicolaus to “Sell”. Morgan Stanley maintained ArcBest Corporation (NASDAQ:ARCB) rating on Wednesday, February 21. Morgan Stanley has “Equal-Weight” rating and $32 target. The stock has “Buy” rating by Cowen & Co on Monday, July 10. The firm has “Neutral” rating given on Monday, November 6 by Buckingham Research. The rating was maintained by Stephens with “Hold” on Thursday, April 12. The firm earned “Neutral” rating on Thursday, February 4 by Citigroup.

ArcBest Corporation provides freight transportation services and integrated logistics solutions worldwide. The company has market cap of $1.26 billion. The company??s Asset-Based segment transports general commodities, such as food, textiles, apparel, furniture, appliances, chemicals, nonbulk petroleum products, rubber, plastics, metal and metal products, wood, glass, automotive parts, machinery, and miscellaneous manufactured products through less-than-truckload services. It has a 21.86 P/E ratio. This segment also offers motor carrier freight transportation services to clients in Mexico through arrangements with trucking companies.

ArcBest Corporation (NASDAQ:ARCB) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.